For cytosolic folate variables and methionine cycle variables, see the discussions in our previous papers [1621]
Low-quality small-sample studies: Preliminary data from small-scale studies should be regarded as avenues for future investigation rather than immediate clinical application
Since then, the evolution of GLP-1 receptor agonists has progressed from initial short-duration agents like exenatide, to intermediate-duration formulations such as liraglutide, and further to advanced long-acting options including dulaglutide and semaglutide (The two products received approval for marketing in the U.S
Embracing these multifaceted strategies will be crucial in improving the lives of those affected by NAFLD
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists
Binding to this allosteric site can still influence the sensitivity and activity of the receptor, but could lead to drugs with fewer off-target side-effects, since GLP-1 is involved in many different metabolic signalling pathways